Anti-Human XEDAR
| Code | Size | Price |
|---|
| LEI-X102-20ug | 20 ug | £199.00 |
Quantity:
| LEI-X102-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Long Description:
XEDAR (X-linked Ectodysplasin A2 Receptor) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and induces apoptosis.1 XEDAR is a receptor for Ectodysplasin-A2 (EDA-A2) which may be a promising agent for the gene therapy of osteosarcoma.2
Target:
XEDAR
References
1. Chaudhary, PM. et al. (2004) J Biol Chem. 279: 41873 2. Chaudhary, PM. et al. (2007) Cancer Gene Ther. 14: 927
Related Products
| Product Name | Product Code | Supplier | Recombinant Human XEDAR | LEI-X111 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|